The lupus anticoagulant and anticardiolipin antibodies are closely related and are directed against negatively charged phospholipids. 1 During the last decade their presence has been associated with a variety of clinical symptoms, known as the antiphospholipid syndrome. 2 The main features of this syndrome are thrombosis, fetal loss, and thrombocytopenia. Most patients with the antiphospholipid syndrome have systemic lupus erythematosus (SLE),3 but it has also been described as a primary syndrome in patients without any underlying disease. 4 Although the pathogenetic potential of antiphospholipid antibodies has not been proven, 5 patients with the antiphospholipid syndrome are increasingly subject to treatment, especially during pregnancy. ' 7 To evaluate the clinical significance of these antibodies, information on the natural course of lupus anticoagulant and anticardiolipin antibodies and their reactions during lupus flares or treatment with prednisone is essential. Previously, we reported the fluctuations of lupus anticardiolipin antibodies in a prospective study of 53 patients with SLE. 8 We showed a significant relation of IgG anticardiolipin antibodies and IgM anticardiolipin antibodies with disease activity in 11 and four patients, respectively. Moreover, it was shown that IgG anticardiolipin antibodies fluctuated in 10 and IgM anticardiolipin antibodies in nine patients with no or mild disease activity during follow up (n=20).
In this study we investigated the incidence of lupus anticoagulant variability in the same cohort of lupus patients in relation to lupus disease activity and treatment with prednisone.
The results were compared with the earlier described findings for anticardiolipin antibodies. 8 Patients and methods PATIENTS patient (fig 3) . In one patient a significant association of treatment with prednisone with the dRWT assay results could be shown.
WHOLE GROUP ANALYSIS
The interrelations between KCT, dRWT, IgG anticardiolipin antibodies, IgM anticardiolipin antibodies and disease activity were examined for the whole group using six random samples (n=318) from each patient (table 2). Significant relations were found between the results of all antiphospholipid antibody assays (X2, p<0*001).
IgG anticardiolipin antibodies were significantly associated with disease activity (p=0046), whereas the results of the KCT, dRVVT, and IgM anticardiolipin assays were not. levels of IgG or IgM anticardiolipin antibodies, from whom at least four samples were obtained during treatment with 20 mg or more of prednisone (n=8, patients 4, 6, 7, 8, 12, 14, 15, 16) . When all available samples of these patients (n= 121), including samples obtained during treatment with less than 20 mg prednisone were considered together, the proportion of positive samples during treatment with high doses of prednisone (¢20 mg) was 19% for the KCT assay, 18% for the dRVVT assay, 29% for IgG anticardiolipin antibodies, and 30% for IgM anticardiolipin antibodies (fig 4) . x2 Analysis testing the independence of assay results (positive or negative) against prednisone dose (>20 and <20 mg) was rejected for the KCT assay (p<0001) and the dRVVT assay (p=0002), but not for the IgG and IgM anticardiolipin antibody assays. (17%) patients. In the remaining six and ten patients, respectively, no apparent cause for the fluctuations of lupus anticoagulant activity during follow up could be given. However 
